Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency

Uwe Kalina, Hans Arnold Stöhr, Heike Bickhard, Sigurd Knaub, Simona M. Siboni, Pier M. Mannucci, Flora Peyvandi

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

To characterize a functional assay for circulating fibrinogen based on rotational thrombelastography. Maximum clot firmness was determined by rotational thrombelastography in normal human plasma pool, fibrinogen-deficient plasma pool, normal whole blood, and individual plasma samples from 17 patients with fibrinogen deficiency. Plasma samples spiked with varying concentrations of exogenous fibrinogen were also measured. Results were compared with enzyme-linked immunosorbent assay and Clauss assay. The impact of sample freezing and filtration and use of cytochalasin D were also investigated. Over the tested range of 0-3 mg/ml added exogenous fibrinogen, the maximum clot firmness standard curve for determination of fibrinogen in plasma pools (n = 7) was linear (r2 = 0.97). Maximum clot firmness was highly linearly correlated both with Clauss assay (r2 = 0.93) and enzyme-linked immunosorbent assay (r2 = 0.95). In unspiked plasma samples from individual patients with fibrinogen deficiency, fibrinogen was undetectable by rotational thromboelastography. By all evaluated methods, the response to spiking with fibrinogen in such samples coincided closely in patients with afibrinogenemia and hypofibrinogenemia. In dysfibrinogenemia, smaller Clauss assay responses to spiking were observed, whereas the enzyme-linked immunosorbent assay response was variable. Maximum clot firmness was the only evaluated method of fibrinogen assessment to yield consistent results across all categories of fibrinogen deficiency. These in-vitro results suggest the potential clinical utility of rotational thromboelastography as a versatile method for monitoring the response to fibrinogen concentrate among patients with fibrinogen deficiency. Clinical investigations using rotational thromboelastography after in-vivo fibrinogen administration to patients with congenital fibrinogen deficiency are warranted.

Original languageEnglish
Pages (from-to)777-783
Number of pages7
JournalBlood Coagulation and Fibrinolysis
Volume19
Issue number8
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Afibrinogenemia
Thrombelastography
Fibrinogen
Therapeutics
Enzyme-Linked Immunosorbent Assay
Cytochalasin D
Freezing

Keywords

  • Afibrinogenemia
  • Clauss assay
  • Dysfibrinogenemia
  • Enzyme-linked immunosorbent assay
  • Fibrinogen
  • Fibrinogen concentrate therapy monitoring
  • Hypofibrinogenemia
  • In vitro
  • Plasma
  • Rotational thromboelastography

ASJC Scopus subject areas

  • Hematology

Cite this

Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. / Kalina, Uwe; Stöhr, Hans Arnold; Bickhard, Heike; Knaub, Sigurd; Siboni, Simona M.; Mannucci, Pier M.; Peyvandi, Flora.

In: Blood Coagulation and Fibrinolysis, Vol. 19, No. 8, 12.2008, p. 777-783.

Research output: Contribution to journalArticle

Kalina, Uwe ; Stöhr, Hans Arnold ; Bickhard, Heike ; Knaub, Sigurd ; Siboni, Simona M. ; Mannucci, Pier M. ; Peyvandi, Flora. / Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. In: Blood Coagulation and Fibrinolysis. 2008 ; Vol. 19, No. 8. pp. 777-783.
@article{656d457fe836430681c0524c4eb4f732,
title = "Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency",
abstract = "To characterize a functional assay for circulating fibrinogen based on rotational thrombelastography. Maximum clot firmness was determined by rotational thrombelastography in normal human plasma pool, fibrinogen-deficient plasma pool, normal whole blood, and individual plasma samples from 17 patients with fibrinogen deficiency. Plasma samples spiked with varying concentrations of exogenous fibrinogen were also measured. Results were compared with enzyme-linked immunosorbent assay and Clauss assay. The impact of sample freezing and filtration and use of cytochalasin D were also investigated. Over the tested range of 0-3 mg/ml added exogenous fibrinogen, the maximum clot firmness standard curve for determination of fibrinogen in plasma pools (n = 7) was linear (r2 = 0.97). Maximum clot firmness was highly linearly correlated both with Clauss assay (r2 = 0.93) and enzyme-linked immunosorbent assay (r2 = 0.95). In unspiked plasma samples from individual patients with fibrinogen deficiency, fibrinogen was undetectable by rotational thromboelastography. By all evaluated methods, the response to spiking with fibrinogen in such samples coincided closely in patients with afibrinogenemia and hypofibrinogenemia. In dysfibrinogenemia, smaller Clauss assay responses to spiking were observed, whereas the enzyme-linked immunosorbent assay response was variable. Maximum clot firmness was the only evaluated method of fibrinogen assessment to yield consistent results across all categories of fibrinogen deficiency. These in-vitro results suggest the potential clinical utility of rotational thromboelastography as a versatile method for monitoring the response to fibrinogen concentrate among patients with fibrinogen deficiency. Clinical investigations using rotational thromboelastography after in-vivo fibrinogen administration to patients with congenital fibrinogen deficiency are warranted.",
keywords = "Afibrinogenemia, Clauss assay, Dysfibrinogenemia, Enzyme-linked immunosorbent assay, Fibrinogen, Fibrinogen concentrate therapy monitoring, Hypofibrinogenemia, In vitro, Plasma, Rotational thromboelastography",
author = "Uwe Kalina and St{\"o}hr, {Hans Arnold} and Heike Bickhard and Sigurd Knaub and Siboni, {Simona M.} and Mannucci, {Pier M.} and Flora Peyvandi",
year = "2008",
month = "12",
doi = "10.1097/MBC.0b013e32830ef90c",
language = "English",
volume = "19",
pages = "777--783",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency

AU - Kalina, Uwe

AU - Stöhr, Hans Arnold

AU - Bickhard, Heike

AU - Knaub, Sigurd

AU - Siboni, Simona M.

AU - Mannucci, Pier M.

AU - Peyvandi, Flora

PY - 2008/12

Y1 - 2008/12

N2 - To characterize a functional assay for circulating fibrinogen based on rotational thrombelastography. Maximum clot firmness was determined by rotational thrombelastography in normal human plasma pool, fibrinogen-deficient plasma pool, normal whole blood, and individual plasma samples from 17 patients with fibrinogen deficiency. Plasma samples spiked with varying concentrations of exogenous fibrinogen were also measured. Results were compared with enzyme-linked immunosorbent assay and Clauss assay. The impact of sample freezing and filtration and use of cytochalasin D were also investigated. Over the tested range of 0-3 mg/ml added exogenous fibrinogen, the maximum clot firmness standard curve for determination of fibrinogen in plasma pools (n = 7) was linear (r2 = 0.97). Maximum clot firmness was highly linearly correlated both with Clauss assay (r2 = 0.93) and enzyme-linked immunosorbent assay (r2 = 0.95). In unspiked plasma samples from individual patients with fibrinogen deficiency, fibrinogen was undetectable by rotational thromboelastography. By all evaluated methods, the response to spiking with fibrinogen in such samples coincided closely in patients with afibrinogenemia and hypofibrinogenemia. In dysfibrinogenemia, smaller Clauss assay responses to spiking were observed, whereas the enzyme-linked immunosorbent assay response was variable. Maximum clot firmness was the only evaluated method of fibrinogen assessment to yield consistent results across all categories of fibrinogen deficiency. These in-vitro results suggest the potential clinical utility of rotational thromboelastography as a versatile method for monitoring the response to fibrinogen concentrate among patients with fibrinogen deficiency. Clinical investigations using rotational thromboelastography after in-vivo fibrinogen administration to patients with congenital fibrinogen deficiency are warranted.

AB - To characterize a functional assay for circulating fibrinogen based on rotational thrombelastography. Maximum clot firmness was determined by rotational thrombelastography in normal human plasma pool, fibrinogen-deficient plasma pool, normal whole blood, and individual plasma samples from 17 patients with fibrinogen deficiency. Plasma samples spiked with varying concentrations of exogenous fibrinogen were also measured. Results were compared with enzyme-linked immunosorbent assay and Clauss assay. The impact of sample freezing and filtration and use of cytochalasin D were also investigated. Over the tested range of 0-3 mg/ml added exogenous fibrinogen, the maximum clot firmness standard curve for determination of fibrinogen in plasma pools (n = 7) was linear (r2 = 0.97). Maximum clot firmness was highly linearly correlated both with Clauss assay (r2 = 0.93) and enzyme-linked immunosorbent assay (r2 = 0.95). In unspiked plasma samples from individual patients with fibrinogen deficiency, fibrinogen was undetectable by rotational thromboelastography. By all evaluated methods, the response to spiking with fibrinogen in such samples coincided closely in patients with afibrinogenemia and hypofibrinogenemia. In dysfibrinogenemia, smaller Clauss assay responses to spiking were observed, whereas the enzyme-linked immunosorbent assay response was variable. Maximum clot firmness was the only evaluated method of fibrinogen assessment to yield consistent results across all categories of fibrinogen deficiency. These in-vitro results suggest the potential clinical utility of rotational thromboelastography as a versatile method for monitoring the response to fibrinogen concentrate among patients with fibrinogen deficiency. Clinical investigations using rotational thromboelastography after in-vivo fibrinogen administration to patients with congenital fibrinogen deficiency are warranted.

KW - Afibrinogenemia

KW - Clauss assay

KW - Dysfibrinogenemia

KW - Enzyme-linked immunosorbent assay

KW - Fibrinogen

KW - Fibrinogen concentrate therapy monitoring

KW - Hypofibrinogenemia

KW - In vitro

KW - Plasma

KW - Rotational thromboelastography

UR - http://www.scopus.com/inward/record.url?scp=57149118055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149118055&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e32830ef90c

DO - 10.1097/MBC.0b013e32830ef90c

M3 - Article

C2 - 19002044

AN - SCOPUS:57149118055

VL - 19

SP - 777

EP - 783

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 8

ER -